Multiple Myeloma: Improved Prognosis With the Latest Treatments
WEBAug 16, 2023 · The overall five-year survival rate for people with active multiple myeloma in the United States has increased steadily over time, to more than 55% today. It’s important to remember that even the most recent statistics apply to many people who did not have access to the newer treatments.
Advances in multiple myeloma treatment - Mayo Clinic …
WEBMay 16, 2024 · Right now, there is no cure for the disease. But as Dr. Joselle Cook, a Mayo Clinic hematologist, explains, recent advances in treatment are helping people live longer. And as multiple myeloma research continues, a cure may someday be on the horizon.
Multiple myeloma: New, better treatments are improving outcomes
WEBApr 27, 2022 · Cancer experts have been exploring and improving multiple myeloma treatments that can extend periods of remission and enhance quality of life.
ASH 2023: A New Standard of Care and Other Advances in …
WEBDec 31, 2023 · Research presented at the ASH Annual Meeting 2023 revealed a new potential standard of care for patients with newly diagnosed multiple myeloma as well as other developments that will inform...
FDA’s Recent Approval of 2 CAR T-Cell Therapies a ‘Big Step …
WEBRye Brook, N.Y., April 16, 2024 – The U.S. Food and Drug Administration (FDA) recently approved the CAR T-cell therapies ciltacabtagene autoleucel (cilta-cel; Carvykti™) and idecabtagene vicleucel (ide-cel; Abecma®) for earlier …
Tecvayli Produces Promising Results in Multiple Myeloma
WEBSep 29, 2022 · Nearly 40% of people with multiple myeloma treated with teclistamab (Tecavayli) had all signs of their cancer disappear, a small clinical trial showed.
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma
WEBMar 30, 2022 · On February 28, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment (refractory) or has returned after treatment (relapsed).
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible …
WEB4 days ago · The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone, a combination known as Isa-VRd, for the treatment of adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT, when a patient’s own stem cells are collected, stored and infused back into them ...
FDA Approves First Cell-Based Gene Therapy for Adult Patients …
WEBMarch 27, 2021. The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded...
Mayo Clinic cancer expert highlights advancements in treating …
WEBMar 20, 2023 · Mayo Clinic researchers continue to test new drugs targeting multiple myeloma as dedicated teams lead clinical trials using new CAR-T cell therapy platforms.
Skip to content